Katayama, Yuki
Yamada, Tadaaki http://orcid.org/0000-0002-6945-281X
Tanimura, Keiko
Tokuda, Shinsaku
Morimoto, Kenji
Hirai, Soichi
Matsui, Yohei
Nakamura, Ryota
Ishida, Masaki
Kawachi, Hayato
Yoneda, Kazue
Hosoya, Kazutaka
Tsuji, Takahiro
Ozasa, Hiroaki
Yoshimura, Akihiro http://orcid.org/0000-0002-3753-2110
Iwasaku, Masahiro
Kim, Young Hak
Horinaka, Mano
Sakai, Toshiyuki
Utsumi, Takahiro
Shiotsu, Shinsuke
Takeda, Takayuki http://orcid.org/0000-0002-8375-6940
Katayama, Ryohei http://orcid.org/0000-0001-7394-895X
Takayama, Koichi http://orcid.org/0000-0002-7723-8960
Funding for this research was provided by:
Pfizer Inc. | Pfizer Japan
MEXT | Japan Society for the Promotion of Science (19K08608)
Medical Research Continuous Grants of Takeda Science Foundation Research Grant of the Princess Takamatsu Cancer Research Fund
Article History
Received: 21 September 2022
Accepted: 11 January 2023
First Online: 26 January 2023
Competing interests
: T.Y. received commercial research grants from Pfizer, Ono Pharmaceutical, Janssen Pharmaceutical K.K., AstraZeneca, and Takeda Pharmaceutical Company Limited and has received speaking honoraria from Eli Lilly. R.K. received research grants from Chugai, Takeda, and TOPPAN outside the submitted work. K. Takayama received research grants from Chugai-Roche and Ono Pharmaceutical and personal fees from AstraZeneca, Chugai-Roche, MSD-Merck, Eli Lilly, Boehringer-Ingelheim, and Daiichi-Sankyo. The other authors disclosed no potential conflicts of interest.